A double-blind, placebo-controlled study of atomoxetine in young children with ADHD
Christopher J Kratochvil, Brigette S Vaughan, Julie A Stoner, Joan M Daughton, Brian D Lubberstedt, Desiree W Murray, Allan K Chrisman, Melissa A Faircloth, Nilda B Itchon-Ramos, Scott H Kollins, Lawrence A Maayan, Laurence L Greenhill, Lisa A Kotler, Jane Fried, John S March, Christopher J Kratochvil, Brigette S Vaughan, Julie A Stoner, Joan M Daughton, Brian D Lubberstedt, Desiree W Murray, Allan K Chrisman, Melissa A Faircloth, Nilda B Itchon-Ramos, Scott H Kollins, Lawrence A Maayan, Laurence L Greenhill, Lisa A Kotler, Jane Fried, John S March
Abstract
Objective: To evaluate the efficacy and tolerability of atomoxetine for the treatment of attention-deficit/hyperactivity disorder (ADHD) in 5- and 6-year-old children.
Methods: This was an 8-week, double-blind, placebo-controlled randomized clinical trial of atomoxetine in 101 children with ADHD. Atomoxetine or placebo was flexibly titrated to a maximum dose of 1.8 mg/kg per day. The pharmacotherapist reviewed psychoeducational material on ADHD and behavioral-management strategies with parents during each study visit.
Results: Significant mean decreases in parent (P = .009) and teacher (P = .02) ADHD-IV Rating Scale scores were demonstrated with atomoxetine compared with placebo. A total of 40% of children treated with atomoxetine met response criteria (Clinical Global Impression-Improvement Scale indicating much or very much improved) compared with 22% of children on placebo, which was not significant (P = .1). Decreased appetite, gastrointestinal upset, and sedation were significantly more common with atomoxetine than placebo. Although some children demonstrated a robust response to atomoxetine, for others the response was more attenuated. Sixty-two percent of subjects who received atomoxetine were moderately, markedly, or severely ill according to the Clinical Global Impression-Severity Scale at study completion.
Conclusions: To our knowledge, this is the first randomized controlled trial of atomoxetine in children as young as 5 years. Atomoxetine generally was well tolerated and reduced core ADHD symptoms in the children on the basis of parent and teacher reports. Reductions in the ADHD-IV Rating Scale scores, however, did not necessarily translate to overall clinical and functional improvement, as demonstrated on the Clinical Global Impression-Severity Scale and the Clinical Global Impression-Improvement Scale. Despite benefits, the children in the atomoxetine group remained, on average, significantly impaired at the end of the study.
Figures
Source: PubMed